# Panbela Therapeutics

Source: https://onco.cc/companies/panbela-therapeutics/  
OnCo record `panbela-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Panbela Therapeutics is a Minnesota biotech whose drug ivospemin starves pancreatic cancer of polyamines, molecules the tumour needs to grow, and is being tested with gemcitabine and nab-paclitaxel in first-line treatment.

## Summary

Panbela Therapeutics, formerly Sun BioPharma, develops polyamine-targeting therapies. Ivospemin (SBP-101) is a polyamine analogue that is taken up preferentially by pancreatic acinar and cancer cells and disrupts polyamine metabolism. The phase 2/3 ASPIRE trial tested ivospemin with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. Through its acquisition of Cancer Prevention Pharmaceuticals it also holds eflornithine-based programmes for familial adenomatous polyposis.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Sun BioPharma; NASDAQ:PBLA
- Tags: drug-maker
- HQ: Waconia, Minnesota
- Type: biotech
- Website: https://www.panbela.com/
- Ticker: NASDAQ:PBLA

## Sources

- Official website: https://www.panbela.com/

## Connected records

- drugs: [Ivospemin](https://onco.cc/drugs/ivospemin/)

---
JSON: https://onco.cc/api/v1/entities/panbela-therapeutics.json